Managed Healthcare Executive1d
FDA Approves First Biosimilar of Novolog
Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...
FDA approves first rapid-acting insulin biosimilar for patients with diabetes
Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with ...
Monthly Prescribing Reference2d
FDA Approves Merilog, a Rapid-Acting Insulin Biosimilar Product
Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.
MyChesCo on MSN4d
FDA Approves Groundbreaking Rapid-Acting Insulin Biosimilar Merilog, Offering New Hope for Millions Battling Diabetes
The U.S. Food and Drug Administration (FDA) recently approved Merilog (insulin-aspart-szjj) as the first rapid-acting insulin ...
Medscape1y
Patient Satisfaction and Costs Associated With Insulin Administered by Pen Device or Syringe During Hospitalization
Patients received the FlexPen if they were randomized to the insulin pen group and prescribed any rapid-acting insulin (insulin lispro or insulin aspart) or the combination of 70% insulin aspart ...
Interesting Engineering on MSN2d
FDA approves first-ever rapid-acting insulin biosimilar for diabetes treatment
The FDA has approved Merilog, the first-ever rapid-acting insulin biosimilar for diabetes treatment that helps manage blood ...
MedPage Today7d
FDA OKs First Rapid-Acting Insulin Biosimilar for Diabetes
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...